2025-06-09-Jefferies-与克里斯·梅森博士和斯特凡·比德尔博士的关键意见领袖晚宴要点_9页_132kb

Equity Research Summary: Life Science Tools & Diagnostics (June 9, 2025)

KOL Dinner Key Insights

• NIH Budget Uncertainty: Chris Mason (Cornell) warned of a worst-case 30-40% budget cut from NIH funding, disproportionately affecting biosurveillance, infectious disease studies, and research involving diversity. Academic labs are scaling back funding efforts, increasing reliance on private donors.
• Roche SBX Threat to Illumina: Both Mason and Dr. Budel highlighted Roche's SBX system as a formidable competitor to Illumina's (ILMN) NGS platform due to its record-fast throughput and superior formalin-fixed paraffin-embedded (FFPE) performance. Potential pricing could be lower than the NovaSeqX, though maintenance, durability, and high GC sequence performance are concerns.
• NGS & Long Reads: Long-read sequencing adoption increased at Mason's lab (from 15% to 30% of work), driven by Oxford Nanopore Technologies (ONT) due to cost and input requirements, displacing Pacific Biosciences. Cost parity with short reads would boost demand.
• Spatial Technology: Viewed as a 5-10 year opportunity rivaling genomics in clinical applications; cost reductions needed. CosMx (BRKR) is gaining share, with improved throughput.

Company-Specific Valuations and Risks

• 10x Genomics (TXG): $16 price target based on DCF, implies ~3x 2025 revenue. Risks include spatial market cannibalization, increased competition, and low product elasticity.
• Bruker Corporation (BRKR): $70 price target, supports ~18x 2025E EV/EBITDA. Risks encompass margin pressure, funding constraints, and innovation uncertainty.
• Illumina (ILMN): $90 price target, HOLD rating. Downside risks include Chinese headwinds, NIH funding uncertainty, and innovation lag; upside could stem from stronger academic budgets.
• Roche (ROG SW): HOLD rating, valuation mix of P/E and NPV. Key risks include R&D inefficiencies, competition, reimbursement challenges, and biosimilar threats.
• Standard BioTools (LAB): $2.25 price target, BUY rating. Risks involve genomics/proteomics competition, integration delays from SLGC deal, and biotech funding weakness.

Analyst Certifications

All analysts certify that their views reflect personal opinions and compensation is not tied to specific recommendations.